8月5日，达维塔保健盘中下跌17.34%，报188.2美元/股，成交额2.92亿美元。
消息面上，公司发布Q2财报，调整后每股收益4.02美元，超出市场预期的3.88美元，同比增长36.27%；营收35.54亿美元，高于预期的34.96亿美元。然而公司维持全年调整后每股收益指引14.10至15.20美元不变，指引中值14.65美元低于市场一致预期的14.88美元。由于Q1和Q2连续大幅超预期，市场此前对上调全年指引抱有较高期待，指引维持不变被解读为隐含下半年盈利增速放缓信号。此外，SEC文件显示伯克希尔·哈撒韦近期出售18.3万股达维塔保健股票，美银将目标价调整至170美元，远低于当前股价，多重利空共振加剧抛压。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.